These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


418 related items for PubMed ID: 18057656

  • 1. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
    Nakamura T.
    Clin Calcium; 2007 Dec; 17(12):1823-9. PubMed ID: 18057656
    [Abstract] [Full Text] [Related]

  • 2. [Parathyroid and bone. Evidence and perspective of parathyroid therapy for patients with osteoporosis].
    Wada S, Fukawa T, Kamiya S.
    Clin Calcium; 2007 Dec; 17(12):1888-94. PubMed ID: 18057665
    [Abstract] [Full Text] [Related]

  • 3. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 4. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 5. A review of combination regimens for osteoporosis--prevention and treatment.
    Miller E, Kalin MF.
    Int J Fertil Womens Med; 2002 May; 47(5):198-204. PubMed ID: 12469706
    [Abstract] [Full Text] [Related]

  • 6. Combination of anabolic and antiresorptive agents for the treatment of osteoporosis.
    Garcés C, García LE.
    Maturitas; 2006 Apr 20; 54(1):47-54. PubMed ID: 16257150
    [Abstract] [Full Text] [Related]

  • 7. The potential of parathyroid hormone as a therapy for osteoporosis.
    Rubin MR, Bilezikian JP.
    Int J Fertil Womens Med; 2002 Apr 20; 47(3):103-15. PubMed ID: 12081255
    [Abstract] [Full Text] [Related]

  • 8. Daily and cyclic parathyroid hormone in women receiving alendronate.
    Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R.
    N Engl J Med; 2005 Aug 11; 353(6):566-75. PubMed ID: 16093465
    [Abstract] [Full Text] [Related]

  • 9. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb 11; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 10. [Treatment of osteoporosis with parathyroid hormone].
    Syversen U, Halse JI.
    Tidsskr Nor Laegeforen; 2008 Jan 03; 128(1):39-41. PubMed ID: 18183056
    [Abstract] [Full Text] [Related]

  • 11. [Regulation of bone mineralization by parathyroid hormone].
    Shimizu M, Tamura T.
    Clin Calcium; 2004 Jun 03; 14(6):70-5. PubMed ID: 15577058
    [Abstract] [Full Text] [Related]

  • 12. [New, pioneering PTH treatment of postmenopausal osteoporosis. Quick effect on bone density and bone formation].
    Törring O.
    Lakartidningen; 2001 Oct 17; 98(42):4552-3. PubMed ID: 11715225
    [No Abstract] [Full Text] [Related]

  • 13. Hetereogeneity in skeletal response to full-length parathyroid hormone in the treatment of osteoporosis.
    Sellmeyer DE, Black DM, Palermo L, Greenspan S, Ensrud K, Bilezikian J, Rosen CJ.
    Osteoporos Int; 2007 Jul 17; 18(7):973-9. PubMed ID: 17333451
    [Abstract] [Full Text] [Related]

  • 14. [Anabolic treatment for osteoporosis: PTH treatment].
    Kaji H, Sugimoto T.
    Clin Calcium; 2006 Sep 17; 16(9):1480-85. PubMed ID: 16951472
    [Abstract] [Full Text] [Related]

  • 15. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.
    Compston JE.
    Bone; 2007 Jun 17; 40(6):1447-52. PubMed ID: 17045858
    [Abstract] [Full Text] [Related]

  • 16. Parathyroid hormone treatment for osteoporosis.
    Cosman F.
    Curr Opin Endocrinol Diabetes Obes; 2008 Dec 17; 15(6):495-501. PubMed ID: 18971677
    [Abstract] [Full Text] [Related]

  • 17. ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis.
    Nemeth EF.
    IDrugs; 2008 Nov 17; 11(11):827-40. PubMed ID: 18988128
    [Abstract] [Full Text] [Related]

  • 18. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr 17; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 19. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR, Bare SP, Smith SY, Varela A, Miller MA, Morris SA, Fox J.
    Bone; 2009 Jan 17; 44(1):113-9. PubMed ID: 18983947
    [Abstract] [Full Text] [Related]

  • 20. Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
    Park JH, Park KH, Cho S, Choi YS, Seo SK, Lee BS, Park HS.
    Menopause; 2013 Jul 17; 20(7):747-53. PubMed ID: 23511701
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 21.